Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:LIFE NASDAQ:OTLK NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.83+1.1%$1.94$1.50▼$2.79$82.65M1.6980,277 shs44,907 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsOTLKOncobiologics$0.97+0.3%$1.74$0.79▼$6.98$43M0.487.39 million shs521,191 shsVXRTVaxart$0.38-0.4%$0.38$0.26▼$0.98$87.34M1.332.70 million shs924,418 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+1.10%+0.55%-5.67%-7.11%-4.19%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics+0.33%-10.07%-63.76%-46.04%-82.59%VXRTVaxart-0.42%-2.18%+9.94%-29.09%-54.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.83+1.1%$1.94$1.50▼$2.79$82.65M1.6980,277 shs44,907 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsOTLKOncobiologics$0.97+0.3%$1.74$0.79▼$6.98$43M0.487.39 million shs521,191 shsVXRTVaxart$0.38-0.4%$0.38$0.26▼$0.98$87.34M1.332.70 million shs924,418 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+1.10%+0.55%-5.67%-7.11%-4.19%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics+0.33%-10.07%-63.76%-46.04%-82.59%VXRTVaxart-0.42%-2.18%+9.94%-29.09%-54.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 4.00Strong Buy$10.00446.45% UpsideLIFEaTyr Pharma 0.00N/AN/AN/AOTLKOncobiologics 2.33Hold$7.00620.76% UpsideVXRTVaxart 3.00Buy$2.00424.25% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, OTLK, VXRT, and LIFE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $8.008/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/11/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$180K464.21N/AN/A$0.23 per share7.96LIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00OTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/AVXRTVaxart$47.40M1.84N/AN/A$0.26 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/AOTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/AVXRTVaxart-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)Latest ENTX, OTLK, VXRT, and LIFE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.4710.47LIFEaTyr Pharma0.026.076.07OTLKOncobiologicsN/A0.670.54VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%LIFEaTyr Pharma61.72%OTLKOncobiologics11.20%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%LIFEaTyr Pharma3.70%OTLKOncobiologics4.80%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2045.66 million40.92 millionOptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionableVXRTVaxart120228.94 million222.37 millionOptionableENTX, OTLK, VXRT, and LIFE HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?September 20, 2025 | marketbeat.comVaxart Announces Withdrawal of Reverse Stock Split ProposalSeptember 19, 2025 | markets.businessinsider.comVaxart, Inc. Withdraws Reverse Stock Split Proposal to Focus on Oral Vaccine DevelopmentSeptember 19, 2025 | quiverquant.comQVaxart Withdraws Proposal, Cancels Stockholder MeetingSeptember 19, 2025 | tipranks.comConcerned Vaxart Stockholders Respond to Inadequate Governance AnnouncementsSeptember 18, 2025 | markets.businessinsider.comVaxart Appoints W. Mark Watson as Lead Independent DirectorSeptember 17, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?September 14, 2025 | marketbeat.comConcerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | markets.businessinsider.comVaxart Reports Promising Phase 1 Results for Second-Generation Norovirus Vaccine Inducing Increased Fecal IgA ResponseSeptember 10, 2025 | quiverquant.comQVaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine CandidateSeptember 10, 2025 | globenewswire.comConcerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | globenewswire.comVaxart Announces Adjournment of Special Meeting of StockholdersSeptember 8, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?September 6, 2025 | marketbeat.comVaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025September 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of DirectorsSeptember 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.September 2, 2025 | globenewswire.comConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board AccountabilitySeptember 2, 2025 | globenewswire.comVaxart Granted Extension by Nasdaq to Regain ComplianceAugust 29, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Here's WhyAugust 29, 2025 | marketbeat.comVaxart Discusses Reverse Stock Split ProposalAugust 21, 2025 | tipranks.comConcerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, OTLK, VXRT, and LIFE Company DescriptionsEntera Bio NASDAQ:ENTX$1.83 +0.02 (+1.10%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$1.86 +0.02 (+1.37%) As of 09/23/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Oncobiologics NASDAQ:OTLK$0.97 +0.00 (+0.33%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$0.98 +0.01 (+1.42%) As of 06:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Vaxart NASDAQ:VXRT$0.38 0.00 (-0.42%) As of 09/23/2025 03:58 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
